Anti-Infectives
Nektar Sells Pulmonary Business to Novartis for $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Published in Medical Device Law Weekly, November 9th, 2008
"This agreement will allow us to focus our efforts on the development of novel therapeutics using our PEGylation and conjugate chemistry-based drug development platforms," said Nektar President and CEO Howard W. Robin. "The transaction also strengthens our balance sheet and significantly reduces expenses. It is a perfect example of our ability to monetize assets that had little future value for Nektar."
Novartis will assume ownership...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
More Articles from Medical Device Law Weekly
- Breast Cancer
Metropolitan Chicago Breast Cancer Task Force Reports on Progress Toward Reducing the Black-White Disparity in Breast Cancer Mortality and Improving Breast Health for All Women - Cardiology
Jacc Intervention Publishes Mivs Vestasync I Trial Preliminary Results - Glancy Binkow & Goldberg Llp
Glancy Binkow & Goldberg LLP, Representing Shareholders of the Spectranetics Corporation, Announces an Expanded Class Period in the Shareholder Lawsuit - Memento, Inc.
Memento and IBM Join Forces to Help Financial Institutions Fight Fraud - NuVasive, Inc.
Nuvasive Reports Third Quarter 2008 Financial Results - Patents
Surgery Tool Maker Sues Rival Over Drill Guide Patent - More from this issue of Medical Device Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
